

SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from *Escherichia coli* as booster induces high titer of neutralizing antibody against SARS coronavirus

Patrick C.Y. Woo^{a,b,c}, Susanna K.P. Lau^{a,b,c}, Hoi-wah Tsoi^a, Zhi-wei Chen^d,
Beatrice H.L. Wong^a, Linqi Zhang^d, Jim K.H. Chan^a, Lei-po Wong^a,
Wei He^e, Chi Ma^e, Kwok-hung Chan^{a,b,c}, David D. Ho^d, Kwok-yung Yuen^{a,b,c,*}

^a Department of Microbiology, The University of Hong Kong, Room 423, University Pathology Building, Queen Mary Hospital, Hong Kong

^b Research Centre of Infection and Immunology, Faculty of Medicine, Hong Kong

^c State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Hong Kong

^d Aaron Diamond AIDS Research Center, NY, USA

^e Peking Union Medical College, Beijing, China

Received 30 December 2004; received in revised form 19 May 2005; accepted 29 May 2005

Available online 13 June 2005

Abstract

Different forms of SARS coronavirus (SARS-CoV) spike protein-based vaccines for generation of neutralizing antibody response against SARS-CoV were compared using a mouse model. High IgG levels were detected in mice immunized with intraperitoneal (i.p.) recombinant spike polypeptide generated by *Escherichia coli* (S-peptide), mice primed with intramuscular (i.m.) tPA-optimize800 DNA vaccine (tPA-S-DNA) and boosted with i.p. S-peptide, mice primed with i.m. CTLA4HingeSARS800 DNA vaccine (CTLA4-S-DNA) and boosted with i.p. S-peptide, mice primed with oral live-attenuated *Salmonella typhimurium* (*Salmonella*-S-DNA-control) and boosted with i.p. S-peptide, mice primed with oral live-attenuated *S. typhimurium* that contained tPA-optimize800 DNA vaccine (*Salmonella*-tPA-S-DNA) and boosted with i.p. S-peptide, and mice primed with oral live-attenuated *S. typhimurium* that contained CTLA4HingeSARS800 DNA vaccine (*Salmonella*-tPA-S-DNA) and boosted with i.p. S-peptide. No statistical significant difference was observed among the Th1/Th2 index among these six groups of mice with high IgG levels. Sera of all six mice immunized with i.p. S-peptide, i.m. DNA vaccine control and oral *Salmonella*-S-DNA-control showed no neutralizing antibody against SARS-CoV. Sera of the mice immunized with i.m. tPA-S-DNA, i.m. CTLA4-S-DNA, oral *Salmonella*-S-DNA-control boosted with i.p. S-peptide, oral *Salmonella*-tPA-S-DNA, oral *Salmonella*-tPA-S-DNA boosted with i.p. S-peptide, oral *Salmonella*-CTLA4-S-DNA and oral *Salmonella*-CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of <1:20–1:160. Sera of all the mice immunized with i.m. tPA-S-DNA boosted with i.p. S-peptide and i.m. CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of \geq 1:1280. The present observation may have major practical value, such as immunization of civet cats, since production of recombinant proteins from *E. coli* is far less expensive than production of recombinant proteins using eukaryotic systems.

© 2005 Elsevier Ltd. All rights reserved.

1. Introduction

Severe acute respiratory syndrome (SARS) has affected 30 countries in five continents with more than 8000 cases and 750 deaths. A novel virus, the SARS coronavirus (SARS-

CoV), has been confirmed to be the etiological agent [1–7]. In addition, we have also reported the isolation of SARS-CoV-like viruses from Himalayan palm civets found in a live animal market in the Guangdong Province of China, which implied that animals could be the reservoir for the ancestor of SARS-CoV [8].

In animal coronavirus infections, it has been shown that the spike proteins of coronaviruses were highly immunogenic,

* Corresponding author. Tel.: +852 28554892; fax: +852 28551241.

E-mail address: hkumicro@hkucc.hku.hk (K. Yuen).

and immunization of animals using spike protein-based vaccines were able to produce neutralizing antibodies that were effective in prevention of infections caused by the corresponding coronaviruses. For SARS-CoV infection, it has been shown that nucleotides 952–1530 of the spike protein gene of SARS-CoV encoded a 193-amino acid fragment responsible for attaching to the receptor for SARS-CoV, angiotensin-converting enzyme 2 [9]. Furthermore, we, and also others, have shown that patients with SARS produced antibody response against the spike protein of SARS-CoV [3,10,11], and it has been demonstrated that the spike protein is the major target for passive immunization [12,13]. In studies that determine the relative importance of humoral and cell mediated immunity for protection against SARS-CoV infection, it was confirmed that neutralizing antibody, when administered by passive immunization, was crucial in conferring protection [14], whereas T-cell immunity was unable to lead to protection [15]. In addition, for vaccine candidates against SARS-CoV, spike protein-based DNA vaccines appeared to be a promising group of vaccine shown to produce protective immunity against SARS-CoV infections, whereas recombinant spike protein vaccines produced by *Escherichia coli* were not efficient in terms of generation of protective immunity as compared to those generated from eukaryotic systems such as transfection of cell lines [14–25]. However, multiple doses of intramuscularly (i.m.) administered DNA vaccine or recombinant protein generated from the eukaryotic systems are quite expensive, and therefore may not be practical in developing countries. No data on less expensive modalities of immunization, such as DNA vaccine followed by boosters of recombinant vaccine produced by *E. coli* or oral mucosal DNA vaccines [26–29], are available.

In this study, we compared the different forms of SARS-CoV spike protein-based vaccines for generation of neutralizing antibody response against SARS-CoV using a mouse model. The relative effectiveness of recombinant spike polypeptide vaccine produced by *E. coli*, two different types of intramuscular spike polypeptide DNA vaccine with and without boosters of recombinant spike polypeptide vaccine produced by *E. coli* and two different types of oral mucosal spike polypeptide DNA vaccine with and without boosters of recombinant spike polypeptide vaccine produced by *E. coli* are compared.

2. Materials and methods

2.1. Animals

Male Balb/c (H-2^d) mice (6–8 weeks old, 18–22 g) were used in all animal experiments. They were housed in cages, under standard conditions with regulated day length, temperature and humidity, and were given pelleted food and tap water ad libitum.

2.2. Recombinant SARS-CoV spike polypeptide vaccine from *E. coli*

Cloning and purification of the spike polypeptide of SARS-CoV was reported previously [3]. Briefly, to produce a plasmid for protein expression, primers (LPW742 5'-CGC-GGATCCGAGTGACCTTGACCGGTGC-3' and LPW931 5'-CGGGGTACCTTAACGTAATAAAGAACTGTATG-3') were used to amplify the gene encoding amino acid residues 14–667 of the spike protein of the SARS-CoV by RT-PCR. This portion of the spike protein was used because it contains the receptor-binding domain within the S1 domain that is highly immunogenic, whereas the complete spike protein was not expressible in *E. coli*. The PCR product was cloned into the *Bam*HI and *Kpn*I sites of vector pQE-31 (Qiagen, Hilden, Germany). The resultant clone was digested by *Pst*I, and the *Pst*I fragment which contained the gene encoding amino acid residues 250–667 of the spike protein was cloned into expression vector pQE-30 (Qiagen, Hilden, Germany) in frame and downstream of the series of six histidine residues. The (His)₆-tagged recombinant spike polypeptide (S-peptide) was expressed and purified using the Ni²⁺-loaded HiTrap Chelating System (Amersham Pharmacia, USA) according to the manufacturer's instructions.

2.3. Human codon usage optimized SARS-CoV DNA vaccines

To enhance the expression of spike polypeptide in human cells, the two SARS-CoV DNA vaccines, tPA-optimize800 (tPA-S-DNA) and CTLA4HingeSARS800 (CTLA4-S-DNA), were constructed using the concept of human codon usage optimization [30] with QUIKChange Multi Site-Directed Mutagenesis Kit (Stratagene, USA) according to manufacturer's instructions. The synthetic polypeptides were cloned into pcDNA3.1(+).

2.4. Oral mucosal tPA-optimize800 and CTLA4HingeSARS800 DNA vaccines

The oral mucosal tPA-optimize800 and CTLA4HingeSARS800 DNA vaccines (*Salmonella*-tPA-S-DNA and *Salmonella*-CTLA4-S-DNA) were prepared according to our published protocol [26,29]. tPA-S-DNA and CTLA4-S-DNA were transformed into auxotrophic *S. typhimurium* aroA strain SL7207 (*S. typhimurium* 2337-65 derivative *hisG46*, DEL 407 [aroA::Tn10{Tc-s}], a gift from Dr Bruce Stocker) [31] by electroporation.

2.5. Transfection of 293 cells with tPA-optimize800 and CTLA4HingeSARS800

Transfection of 293 cells with tPA-S-DNA and CTLA4-S-DNA was performed according to our published protocol [26,29]. Two hundred and ninety-three cells were

plated at 1×10^7 cells per well in Dulbecco's modified Eagle's medium (GibcoBRL, USA) with 10% fetal calf serum (FCS) in a six-well plate on the day before transfection. On the day of transfection, each well was transfected with 1 µg plasmid encoding eukaryotically expressed SARS-CoV spike polypeptide (tPA-S-DNA or CTLA4-S-DNA) or pcDNA3.1(+) (S-DNA-control) with FuGENE 6 Reagent (Boehringer Mannheim, Germany) according to manufacturer's instructions. Forty-eight hours after transfection, the cells were harvested and lysed by freezing and thawing three times. After centrifugation at 14000 rpm, the supernatant was used for the detection of SARS-CoV spike polypeptide by Western blot assay using pre-immune rabbit serum and hyperimmune polyclonal serum from rabbit immunized with S-peptide.

2.6. Western blot analysis

Western blot analysis was performed according to our published protocol [29]. Briefly, 10 µl of supernatant of 293 cell lysates obtained from 293 cells transfected with tPA-S-DNA, CTLA4-S-DNA or S-DNA-control was loaded into each well of a sodium dodecyl sulfate (SDS)–8% polyacrylamide gel and subsequently electroblotted onto a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). The blot was incubated separately with 1:1000 dilution of pre-immune rabbit serum or hyperimmune polyclonal serum from rabbit immunized with S-peptide. Antigen–antibody interaction was detected with an ECL fluorescence system (Amersham Life Science, Buckinghamshire, UK).

2.7. Immunization schedule

Seventy-two Balb/c mice were used for the immunization experiments. The immunization schedule is summarized in Table 1. On days 0, 14 and 28, six mice were immunized intraperitoneally (i.p.) with S-peptide [0.5 µg per mouse (Group 1, Table 1)]. On day 0, six mice were immunized i.m. (tibialis anterior muscle) with S-DNA-control [100 µg per mouse (Group 2, Table 1)] and 12 mice each were immunized i.m. with tPA-S-DNA [100 µg per mouse (Group 3, Table 1)] or CTLA4-S-DNA [100 µg per mouse (Group 5, Table 1)]. On days 28 and 42, 6 of the 12 mice in the two DNA vaccine groups were boosted with i.p. S-peptide [0.5 µg per mouse (Groups 4 and 6, Table 1)]. On day 0, 12 mice each were immunized orally with *S. typhimurium* aroA strain (Salmonella-S-DNA-control) [6×10^9 bacterial cells per mouse (Group 7, Table 1)], *Salmonella*-tPA-S-DNA [6×10^9 bacterial cells per mouse (Group 9, Table 1)] or *Salmonella*-CTLA4-S-DNA [6×10^9 bacterial cells per mouse (Group 11, Table 1)]. On days 28 and 42, 6 of the 12 mice in the three groups were boosted with i.p. S-peptide [0.5 µg per mouse (Groups 8, 10 and 12, Table 1)].

Table 1
Immunization schedule for different forms of spike polypeptide-based vaccines against SARS-CoV

Groups	First dose (day 0)			Second dose			Third dose		
	Vaccines	Routes of administration	Dose per mouse	Vaccines	Routes (days) of administration	Dose per mouse	Vaccines	Routes (days) of administration	Dose per mouse
1	Spike polypeptide	Intraperitoneal	50 µg	Spike polypeptide	Intraperitoneal (14)	50 µg	Spike polypeptide	Intraperitoneal (28)	50 µg
2	pcDNA3.1(+)	Intramuscular	100 µg	–	–	–	–	–	–
3	tPA-optimize800 DNA vaccine	Intramuscular	100 µg	–	–	–	–	–	–
4	tPA-optimize800 DNA vaccine	Intramuscular	100 µg	Spike polypeptide	Intraperitoneal (28)	50 µg	Spike polypeptide	Intraperitoneal (42)	50 µg
5	CTLA4HingeSA RS800 DNA vaccine	Intramuscular	100 µg	–	–	–	–	–	–
6	CTLA4HingeSA RS800 DNA vaccine	Intramuscular	100 µg	Spike polypeptide	Intraperitoneal (28)	50 µg	Spike polypeptide	Intraperitoneal (42)	50 µg
7	<i>S. typhimurium</i> aroA strain	Oral	6×10^9 bacterial cells	–	–	–	–	–	–
8	<i>S. typhimurium</i> aroA strain	Oral	6×10^9 bacterial cells	Spike polypeptide	Intraperitoneal (28)	50 µg	Spike polypeptide	Intraperitoneal (42)	50 µg
9	Mucosal tPA-optimize800 DNA vaccine	Oral	6×10^9 bacterial cells	–	–	–	–	–	–
10	Mucosal tPA-optimize800 DNA vaccine	Oral	6×10^9 bacterial cells	Spike polypeptide	Intraperitoneal (28)	50 µg	Spike polypeptide	Intraperitoneal (42)	50 µg
11	Mucosal CTLA4HingeSA RS800DNA vaccine	Oral	6×10^9 bacterial cells	–	–	–	–	–	–
12	Mucosal CTLA4HingeSA RS800 DNA vaccine	Oral	6×10^9 bacterial cells	Spike polypeptide	Intraperitoneal (28)	50 µg	Spike polypeptide	Intraperitoneal (42)	50 µg

2.8. Measurement of serum antibodies against SARS-CoV spike polypeptide

Mice from each group were bled on the day before immunization and 42 days after the last dose of vaccine in the corresponding group. The blood was centrifuged at $2700 \times g$ for 20 min and the supernatant (serum) was stored at -70°C before antibody measurement.

Antibodies against SARS-CoV spike polypeptide were measured using the enzyme-linked immunosorbent assay (ELISA) according to our published protocol with modifications [3,4]. Mouse sera (diluted with PBS-2% skim milk, 1:10 for IgM, 1:80 for IgG, 1:1280 for IgG1, 1:40 for IgG2a, 1:10 for IgG2b and 1:320 for IgG3) were added to ELISA plates precoated with S-peptide (80 ng per well for IgM, IgG, IgG2a, IgG2b and IgG3 and 10 ng per well for IgG1). The plates were incubated at 37°C for 1 h. After washing with washing buffer five times, 100 μl peroxidase-conjugated goat anti-mouse IgM and IgG, rabbit anti-mouse IgG1, IgG2a and IgG3 and rat anti-mouse IgG2b antibody (Zymed Laboratories Inc., USA) diluted according to manufacturer's instructions using PBS-2% skim milk were added to the corresponding wells accordingly and incubated at 37°C for 1 h. IgM and total IgG levels were assayed to assess the primary and secondary immune response, while the IgG subtypes were used to determine whether the humoral response was inclined towards the Th1 (IgG2a and IgG2b) or Th2 (IgG1 and IgG3) pattern. After washing with washing buffer five times, 100 μl diluted 3,3',5,5'-tetramethylbenzidine (Zymed Laboratories Inc.) was added to each well and incubated at room temperature for 15 min. One hundred microliters of 0.3 M H_2SO_4 was added and the absorbance at 450 nm of each well was measured. Each sample was tested in duplicate and the mean absorbance for each serum was calculated. The serum antibody level of a particular mouse was defined as the absorbance obtained from the serum taken 42 days after the last dose of the vaccine minus that of the corresponding mouse taken the day before immunization. The Th1/Th2 index of each mouse is calculated by the following formula: $\text{IgG2a} \times \text{IgG2b}/\text{IgG1} \times \text{IgG3}$.

2.9. Neutralizing antibody assay

The neutralizing antibody assay was modified from our published protocol [32]. All work with infectious virus was performed inside a type II Biosafety Cabinet, in a Biosafety Containment level III facility, and the personnel wore powered air-purifying respirators (HEPA Airmate, 3M, St. Paul, MN). Initial screening of mouse sera against the prototype SARS-CoV strain no. 39849 was performed in 96-well microtiter plates seeded with fetal rhesus kidney-4 cells. Two-fold dilutions of mouse sera (from 1:20 to 1:1280) were tested in duplicate against 100 TCID₅₀ of SARS-CoV. A corresponding set of cell controls with sera but without virus inoculation was used as controls. The cells were scored for the inhibition of the cytopathic effect (CPE) at 48 h. The titer

of neutralizing antibody is defined as the maximum dilution of serum at which the percentage of CPE is less than or equal to 50%.

2.10. Measurement of lymphocyte proliferation index (LPI)

LPI was measured according to our published protocol [29]. On day 60, single-cell suspensions of spleen cells from the six mice of each group were depleted of erythrocytes by adding freshly prepared Gey's solution. The cells were resuspended in RPMI 1640 medium (Gibco BRL, Rockville, MD) supplemented with 15% fetal calf serum and inoculated into microwell plates at 5×10^5 cells per well in triplicate. Cells were stimulated with phytohaemagglutinin at 5 μg per well (positive control), S-peptide at 0.1 μg per well or RPMI medium (negative control). Cells were cultured at 37°C 5% CO_2 for 3 days, and ^3H -labelled thymidine (Amersham Pharmacia, Little Chalfont, UK) was added at 1 μCi per well for the last 18 h. Cells were harvested onto glass microfibre filter (Whatman International Ltd., UK) using a Model CH1 cell harvester (Insel, Hampshire, UK) and radioactivity was measured by a liquid scintillation counter (Beckman, Fullerton, CA). The S-peptide-specific LPI of a particular sample is defined as the ratio of the difference of radioactivity between the sample and the negative control and that between the positive and negative controls.

2.11. Interleukin-4 (IL-4) and interferon- γ (IFN- γ) assays

IL-4 and IFN- γ were assayed according to our published protocol [29]. On day 60, spleens from the six mice in each group were harvested. Single-cell suspensions were prepared and cells from mice within the same group were pooled. 2×10^6 cells were cultured in 1 ml RPMI 1640 medium supplemented with 10% fetal calf serum and 5×10^{-5} M 2-mercaptoethanol in 24-well plates. S-peptide was added at final concentrations of 0.5, 1.0 and 2.5 $\mu\text{g}/\text{ml}$. Supernatant (200 μl) from each sample was collected at 24, 48 and 72 h for cytokine measurement. Monoclonal antibodies against IL-4 or IFN- γ were coated onto wells in 96-well microtiter plates (OptEIA, PharM3ingen, Becton Dickinson, USA) at 1:250 dilutions according to manufacturer's instructions. The plates were incubated at RT for 24 h. After washing with washing buffer three times, the plates were blocked with assay diluent at RT for 1 h. After washing with washing buffer three times, 100 μl of supernatant from each sample was added to the wells in duplicate. The plates were incubated at RT for 2 h. After washing with washing buffer five times, 100 μl diluted biotinylated antibody against IL-4 or IFN- γ and avidin-horseradish peroxidase conjugate were added to the wells and incubated at RT for 1 h. After washing with washing buffer eight times, 100 μl TMB substrate was added to each well and incubated at RT for 30 min. Hundred micro-

liters of 0.3 M H₂SO₄ was added and the absorbance of each well was measured at 450 nm, using TMB buffer as a blank. Each pooled sample was tested in triplicate and the mean absorbance for each pooled sample was calculated.

2.12. Statistical analysis

Comparison was made among the serum antibody levels and LPI of the various groups of mice using one-way ANOVA. $P < 0.05$ was regarded as statistically significant.

3. Results

3.1. SARS-CoV spike polypeptide expression in 293 cells transfected with tPA-optimize800 and CTLA4HingeSARS800

The supernatant of 293 cell lysates obtained from 293 cells transfected with tPA-S-DNA, CTLA4-S-DNA or S-DNA-control were separated on SDS–polyacrylamide gels followed by Western blot analysis with sera from pre-immune rabbit serum or hyperimmune polyclonal serum from rabbit immunized with S-peptide. Prominent immunoreactive protein bands of about 90 and 110 kDa were visible on the Western blot that used cell lysates obtained from 293 cells transfected with tPA-S-DNA and CTLA4-S-DNA, respectively, as the antigen and hyperimmune polyclonal serum from rabbit immunized with S-peptide as the source of antibody (Fig. 1, lanes 1 and 2). These sizes were consistent with the expected size of 91.4 and 108.1 kDa for the corresponding spike polypeptides.

3.2. Antibody response

The antibody levels of the 12 groups of mice on day 42 were summarized in Fig. 2. No IgG was detected in mice of Groups 2, 3, 5, 7, 9 and 11, whereas high IgG levels were detected in mice of Groups 1, 4, 6, 8, 10 and 12. No statistical significant difference was observed among the Th1/Th2 index among these six groups of mice with high IgG levels.

3.3. Neutralizing antibody assay

The number of mice with different neutralizing antibody titers immunized with different forms of spike polypeptide-based vaccines against SARS-CoV was shown in Table 2. Sera of all the six mice immunized with i.p. S-peptide, i.m. S-DNA-control and oral *Salmonella*-S-DN A-control (Groups, 1, 2 and 7) showed no neutralizing antibody against SARS-CoV. Sera of the mice immunized with i.m. tPA-S-DNA, i.m. CTLA4-S-DNA, oral *Salmonella*-S-DNA-control boosted with i.p. S-peptide,




Fig. 1. Prominent immunoreactive protein bands of about 90 and 110 kDa were visible on the Western blot (lanes 1 and 2), indicating antigen–antibody interactions between the 293 cell lysates obtained from 293 cells transfected with tPA-optimize800 and CTLA4HingeSARS800, respectively, and hyperimmune polyclonal serum from rabbit immunized with (His)₆-tagged recombinant spike polypeptide. No antigen–antibody interactions were observed between the 293 cell lysates obtained from 293 cells transfected with tPA-optimize800 or CTLA4HingeSARS800 and the pre-immune rabbit serum (lanes 3 and 4).

oral *Salmonella*-tPA-S-DNA, oral *Salmonella*-tPA-S-DNA boosted with i.p. S-peptide, oral *Salmonella*-CTLA4-S-DNA and oral *Salmonella*-CTLA4-S-DNA boosted with i.p. S-peptide (Groups, 3, 5 and 8–12) showed neutralizing antibody titers of $< 1:20$ – $1:160$. Sera of all the mice immunized with i.m. tPA-S-DNA boosted with i.p. S-peptide and i.m. CTLA4-S-DNA boosted with i.p. S-peptide (Groups 4 and 6) showed neutralizing antibody titers of $\geq 1:1280$.

3.4. Lymphocyte proliferation index

The S-peptide-specific LPI of the 12 groups of mice on day 60 were summarized in Fig. 3. Significant lymphocyte proliferation was detected in Groups 1, 3, 4, 5, 6, 8, 9, 10, 11 and 12, compared to the control groups (Groups 2 and 7).

3.5. Interleukin-4 and interferon- γ assays

At 24 h, IL-4 was undetectable in all 12 groups of mice for all three concentrations of S-peptide (data not shown). At 48 h, IL-4 was detectable only in mice of Groups 6, 8 and 12 (data not shown). At 72 h, IL-4 was detectable in mice of Groups 1, 5, 6, 8, 9, 10 and 12 (Fig. 4).

At 24 h, the IFN- γ levels of the 12 groups of mice are shown in Fig. 4. IFN- γ was detectable in mice of Groups 1, 3, 4, 5, 6, 8, 9, 10, 11 and 12. At 48 and 72 h, the IFN- γ levels mice of Groups 1, 4, 5, 6, 8, 10, 11 and 12 were all > 6000 pg/ml (data not shown).




Fig. 2. Serum antibody levels (O.D. 450) at day 42 in the 12 groups of Balb/c mice immunized with the various vaccines. The 12 groups correspond to the 12 groups of mice described in Table 1 (bar = average of six mice, error bar = 1 standard deviation).

4. Discussion

Among all the combinations of vaccines examined in this study, mice primed with SARS-CoV human codon usage optimized spike polypeptide DNA vaccines and boosted with S-peptide produced by *E. coli* generated the highest titer of neutralizing antibody against SARS-CoV. It has been observed, and is confirmed in the present study, that S-peptide produced by *E. coli* did not induce neutralizing antibody against SARS-CoV infection (Table 2, Group 1). On the other

hand, recombinant spike polypeptide generated by eukaryotic systems such as transfection of COS7 and BHK21 cells or DNA vaccine was able to elicit high neutralizing antibody titer against SARS-CoV infection [15,21,24]. This was probably because when S-peptide produced by *E. coli* was used, the three dimensional folding and/or the glycosylation of the S-peptide was not optimal for the generation of neutralizing antibodies. In this study, we documented that although recombinant S-peptide produced by *E. coli* itself was not able to generate neutralizing antibody against SARS-CoV

Table 2
Neutralizing antibody titers for different forms of spike polypeptide-based vaccines against SARS-CoV

Groups	Neutralizing antibody titers (no. of mice)							
	<1:20	1:20	1:40	1:80	1:160	1:320	1:640	≥1:1280
1 (S-peptide)	6	0	0	0	0	0	0	0
2 (S-DNA-control)	6	0	0	0	0	0	0	0
3 (tPA-S-DNA)	0	2	0	0	4	0	0	0
4 (tPA-S-DNA boosted with S-peptide)	0	0	0	0	0	0	0	6
5 (CTLA4-S-DNA)	0	4	2	0	0	0	0	0
6 (CTLA4-S-DNA boosted with S-peptide)	0	0	0	0	0	0	0	6
7 (<i>Salmonella</i> -S-DNA-control)	6	0	0	0	0	0	0	0
8 (<i>Salmonella</i> -S-DNA-control boosted with S-peptide)	0	2	0	4	0	0	0	0
9 (<i>Salmonella</i> -tPA-S-DNA)	4	2	0	0	0	0	0	0
10 (<i>Salmonella</i> -tPA-S-DNA boosted with S-peptide)	2	1	2	1	0	0	0	0
11 (<i>Salmonella</i> -CTLA4-S-DNA)	5	1	0	0	0	0	0	0
12 (<i>Salmonella</i> -CTLA4-S-DNA boosted with S-peptide)	2	2	1	0	1	0	0	0

infection, mice primed with spike polypeptide DNA vaccine and boosted with S-peptide from *E. coli* were able to generate high titer of neutralizing antibody against SARS-CoV (Table 2, Groups 4 and 6). This indicates that the type of vaccine used for priming is crucial in determining the type of immune response developed. Subsequent doses will booster the immune response generated by the first dose of vaccine. Of note is that the humoral immune response developed in mice primed with spike polypeptide DNA vaccine and boosted with S-peptide from *E. coli* was not particularly of the Th1 type as compared to that developed in mice immunized with S-peptide from *E. coli* alone. This indicates that a Th1 type immune response may not be essential for the generation of neutralizing antibodies against SARS-CoV. Although our results suggest that priming with DNA vaccines and boosting with S-peptide produced by *E. coli* was successful in the generation of neutralizing antibody against SARS-CoV, further experiments using infection models to evaluate its protective immunity are warranted, since anti-spike antibodies have been shown to enhance the infectivity of coronaviruses

in some cell culture systems, as occurred with SARS-CoV and feline infectious peritonitis virus [33,34].

The present observation may have major practical value, such as immunization of civet cats, as production of recombinant proteins from *E. coli* is far less expensive than production of recombinant proteins using eukaryotic systems such as transfection of cell lines or DNA vaccines. Although it has been shown that DNA vaccines are able to generate both humoral and cellular immunity successfully for various pathogens in mice, one of the major limitations for its clinical use is its ineffectiveness when it is used in humans, unless a large amount of DNA is used for immunization [35,36]. As for the production of recombinant spike polypeptide generated by eukaryotic systems such as transfection of COS7 and BHK21 cells [24] or using the baculovirus system [25], although the conformation and/or glycosylation of the spike polypeptide produced can theoretically be more similar to the native viral spike protein, it is not easy to scale up the production of such recombinant proteins to industrial levels. In contrast to recombinant spike polypeptide generated




Fig. 3. SARS-CoV spike polypeptide-specific lymphocyte proliferation index of Balb/c mice immunized with the various vaccines. The 12 groups correspond to the 12 groups of mice described in Table 1 (bar = average of six mice, error bar = 1 standard deviation).




Fig. 4. IL-4 (at 72 h) and Interferon- γ (at 24 h) levels of splenic cell culture supernatant in Balb/c mice immunized with the various vaccines. The 12 groups correspond to the 12 groups of mice described in Table 1.

by eukaryotic systems, a large amount of S-peptide can be produced by *E. coli* in a relatively inexpensive way, and such S-peptide can be used successfully as boosters. Further studies on the effectiveness of this mode of vaccination for generation of protective immunity against SARS-CoV in other animals could be performed. This principle can also be examined in vaccination for other pathogens, where “more effective” modalities of vaccination, such as DNA vaccine, can be used for priming, and the “less expensive” recombinant protein produced by *E. coli*, instead of eukaryotic systems, can be used as boosters.

Spike polypeptide DNA vaccines delivered by the live-attenuated *Salmonella* system did not induce good neutralizing antibody against SARS-CoV infection. We have previously shown that hepatitis B virus DNA vaccine presented by the live-attenuated *Salmonella* system generated good cytotoxic T lymphocyte response, but minimal antibody response, against hepatitis B virus in a mouse model [26,27]. Furthermore, we found that this immune response was able to down-regulate transgene expression in hepatitis B virus surface antigen transgenic mice [28]. Subsequently,

we reported a comparison of the efficacy of DNA vaccine, DNA vaccine delivered by the live-attenuated *Salmonella* system and recombinant protein vaccine for generation of protective immune response against *Penicillium marneffei*, a thermal dimorphic fungus infecting 10% of HIV positive patients in China and Southeast Asia, in a mouse model [29]. Results showed that, similar to hepatitis B virus DNA vaccine presented by the live-attenuated *Salmonella* system, *P. marneffei* DNA vaccine delivered by the live-attenuated *Salmonella* system did not generate good antibody response, whereas intramuscular DNA vaccine generated the best protective immunity against *P. marneffei* infection, implying that both cellular and humoral immune response are important for protection against *P. marneffei* infection [29]. In the present study, it was observed that, in line with the results of hepatitis B virus DNA vaccine and *P. marneffei* DNA vaccine delivered by the live-attenuated *Salmonella* system, spike polypeptide DNA vaccines delivered by the live-attenuated *Salmonella* system did not induce good antibody response (Fig. 2 and Table 2, Groups 9 and 11). Although the mice developed high antibody levels against the spike protein after boosting with

S-peptide (Fig. 2, Groups 10 and 12), the antibodies were not neutralizing in our cell culture system (Table 2, Groups 10 and 12). This may be due to the ineffectiveness of the DNA vaccine delivered by the live-attenuated *Salmonella* system in priming the development of neutralizing antibodies in the correct configuration, while the “non-neutralizing” antibodies against the spike protein were only elicited in response to the subsequent recombinant S-peptide.

Acknowledgements

This work was partly supported by the Research Fund for the Control of Infectious Diseases of the Health, Welfare and Food Bureau of the Hong Kong SAR Government 01030282, SARS Research Fund, University SARS Donation Fund and the Research Grant Council Grant.

References

- [1] Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. *Lancet* 2003;361(9366):1319–25.
- [2] Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. *Lancet* 2003;361(9371):1767–72.
- [3] Woo PC, Lau SK, Tsoi HW, Chan KH, Wong BH, Che XY, et al. Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. *Lancet* 2004;363(9412):841–5.
- [4] Woo PC, Lau SK, Wong BH, Tsoi HW, Fung AM, Chan KH, et al. Detection of specific antibodies to severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein for serodiagnosis of SARS coronavirus pneumonia. *J Clin Microbiol* 2004;42(5):2306–9.
- [5] Lau SK, Woo PC, Wong BH, Woo GK, Poon RW, Tsoi HW, et al. Detection of severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in SARS patients by enzyme-linked immunosorbent assay. *J Clin Microbiol* 2004;42(7):2884–9.
- [6] Woo PC, Lau SK, Wong BH, Chan KH, Chu CM, Tsoi HW, et al. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. *Clin Diagn Lab Immunol* 2004;11(4):665–8.
- [7] Woo PC, Lau SK, Wong BH, Chan KH, Hui WT, Kwan GS, et al. False-positive results in recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E rectified by Western blotting with recombinant SARS-CoV spike polypeptide. *J Clin Microbiol* 2004;42(12):5885–8.
- [8] Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. *Science* 2003;302(5643):276–8.
- [9] Wong SK, Li W, Moore MJ, Choe H, Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. *J Biol Chem* 2004;279(5):3197–201.
- [10] Huang LR, Chiu CM, Yeh SH, Huang WH, Hsueh PR, Yang WZ, et al. Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting of ELISA. *J Med Virol* 2004;73(3):338–46.
- [11] Hsueh PR, Kao CL, Lee CN, Chen LK, Ho MS, Sia C, et al. SARS antibody test for serosurveillance. *Emerg Infect Dis* 2004;10(9):1558–62.
- [12] Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. *Nat Med* 2004;10(8):871–5.
- [13] ter Meulen J, Bakker AB, van den Brink EN, Weverling GJ, Martina BE, Haagmans BL, et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. *Lancet* 2004;363(9427):2139–41.
- [14] Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. *Proc Natl Acad Sci USA* 2004;101(17):6641–6.
- [15] Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. *Nature* 2004;428(6982):561–4.
- [16] Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. *Proc Natl Acad Sci USA* 2004;101(26):9804–9.
- [17] Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St Claire M, et al. Mucosal immunisation of African green monkeys (*Cercopithecus aethiops*) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. *Lancet* 2004;363(9427):2122–7.
- [18] Gao W, Tamin A, Soloff A, D’Aiuto L, Nwanegbo E, Robbins PD, et al. Effects of a SARS-associated coronavirus vaccine in monkeys. *Lancet* 2003;362(9399):1895–6.
- [19] Kim TW, Lee JH, Hung CF, Peng S, Roden R, Wang MC, et al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. *J Virol* 2004;78(9):4638–45.
- [20] Tang L, Zhu Q, Qin E, Yu M, Ding Z, Shi H, et al. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. *DNA Cell Biol* 2004;23(6):391–4.
- [21] Zeng F, Chow KY, Hon CC, Law KM, Yip CW, Chan KH, et al. Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments. *Biochem Biophys Res Commun* 2004;315(4):1134–9.
- [22] Zhu MS, Pan Y, Chen HQ, Shen Y, Wang XC, Sun YJ, et al. Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine. *Immunol Lett* 2004;92(3):237–43.
- [23] Zhang H, Wang G, Li J, Nie Y, Shi X, Lian G, et al. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. *J Virol* 2004;78(13):6938–45.
- [24] Song HC, Seo MY, Stadler K, Yoo BJ, Choo QL, Coates SR, et al. Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. *J Virol* 2004;78(19):10328–35.
- [25] Mortola E, Roy P. Efficient assembly release of SARS coronavirus-like particles by a heterologous expression system. *FEBS Lett* 2004;576(1–2):174–8.
- [26] Woo PC, Wong LP, Zheng BJ, Yuen KY. Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated *Salmonella typhimurium*. *Vaccine* 2001;19(20–22):2945–54.
- [27] Zheng BJ, Woo PCY, Ng MH, Tsoi HW, Wong LP, Yuen KY. A crucial role of macrophages in the immune responses to oral DNA vaccination against hepatitis B virus in a murine model. *Vaccine* 2001;20(1–2):140–7.
- [28] Zheng BJ, Ng MH, Chan KW, Tam S, Woo PCY, Ng SP, et al. A single dose of oral DNA immunization delivered by attenuated *Salmonella typhimurium* down-regulates transgenic expression in HBsAg transgenic mice. *Eur J Immunol* 2002;32(11):3294–304.

- [29] Wong LP, Woo PC, Wu AY, Yuen KY. DNA immunization using a secreted cell wall antigen Mplp is protective against *Penicillium marneffei* infection. *Vaccine* 2002;20(23–24):2878–86.
- [30] Deml L, Bojak A, Steck S, Graf M, Wild J, Schirmbeck R, et al. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. *J Virol* 2001;75(22):10991–1001.
- [31] Hoiseth SK, Stocker BA. Aromatic-dependent *Salmonella typhimurium* are non-virulent and effective as live vaccines. *Nature* 1981;291(5812):238–9.
- [32] Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, Fan KW, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. *J Clin Virol* 2004;31(1):69–75.
- [33] Olsen CW, Corapi WV, Ngichabe CK, Baines JD, Scott FW. Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. *J Virol* 1992;66(2):956–65.
- [34] Yang ZY, Werner HC, Kong WP, Leung K, Traggiai E, Lanzavecchia A, et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. *Proc Natl Acad Sci USA* 2005;102(3):797–801.
- [35] Manoj S, Babiuk LA, van Drunen Littel-van den Hurk S. Approaches to enhance the efficacy of DNA vaccines. *Crit Rev Clin Lab Sci* 2004;41(1):1–39.
- [36] Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M, et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. *J Immunol* 2000;165(5):2850–8.